All In Biotech

Drug Trial Radar · NCT07883213

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK139 in Subjects With Prurigo Nodularis

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis. The total duration of the study (including screening period, treatment period and follow-up period) planned for each subject is approximately 24 weeks.

Conditions

  • Prurigo Nodularis (PN)

Interventions

  • AK139Biological

    Biological: AK139 low dose

  • PlaceboOther

    Other: Placebo

  • AK139Biological

    Biological: AK139 high dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with ≥4-point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at week 16Time frame: Up to week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.